Home
About
Overview
Sharing Data
ORCID
Help
History (17)
Invited commentary.
Interstitial flow and its effects in soft tissues.
Myasthenia gravis induced by avelumab.
mHealth Interventions for Disadvantaged and Vulnerable People with Type 2 Diabetes.
Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients.
See All 17 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients.
Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients. HPB (Oxford). 2010 Dec; 12(10):657-63.
View in:
PubMed
subject areas
Acute Disease
Adult
Aged
Analysis of Variance
Antiviral Agents
Baltimore
Chi-Square Distribution
Cytomegalovirus Infections
Drug Administration Schedule
Female
Ganciclovir
Graft Rejection
Humans
Immunosuppressive Agents
Incidence
Kaplan-Meier Estimate
Liver Transplantation
Male
Middle Aged
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Young Adult
authors with profiles
Rolf Barth